| Description | Diflomotecan (BN 80915) is a potent, orally active topoisomerase I inhibitor that displays enhanced plasma stability and superior preclinical anti-tumor activity relative to other established compounds. |
| Synonyms | BN 80915 |
| molecular weight | 398.36 |
| Molecular formula | C21H16F2N2O4 |
| CAS | 186668-70-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009;18(1):69-75. 2. Gelderblom H, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res. 2003;9(11):4101-4107. |